RBC Capital on ADC Therapeutics (ADCT): 'A Critical Year Ahead for Zynlonta Expansion De-Risking'

RBC Capital analyst Gregory Renza reiterated an Outperform rating and $8.00 price target on ADC Therapeutics (NYSE: ADCT).

The analyst commented: "A Critical Year Ahead for Zynlonta Expansion De-Risking, Share Re-Rating; Zynlonta's 4Q24 sales of $16.4M were below our/cons $18.6M/ $19.2M estimates, which reflects the persistent competition from CD20 bispecifics in 3L+ DLBCL, in our view, though sights are set on the path to expanding the clinical utility for the long-term in the face of a shifting landscape. From the call, we note a reiteration of LOTIS-5 data update in late-2025, which we see as a key catalyst given its potential to broaden Zynlonta's revenue base. On deck, we look to LOTIS-7 updates in 2Q25 and full data in 2H25, as well as incremental updates at AACR in April. We adjust the model per the Q updates and maintain our Outperform, Speculative Risk rating, and $8 PT."

For an analyst ratings summary and ratings history on ADC Therapeutics click here. For more ratings news on ADC Therapeutics click here.

Shares of ADC Therapeutics closed at $1.52 yesterday.

You May Also Be Interested In

• ADC Therapeutics (ADCT) PT Lowered to $5 at Guggenheim
• UBS Downgrades Planisware SA (PLNW:FP) to Neutral
• HSBC Upgrades Blue Star Limited (BLSTR:IN) to Buy